C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2018
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Pipeline Review, H2 2018
SUMMARY
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production.
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Oncology, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Musculoskeletal Disorders and Respiratory which include indications Alzheimer's Disease, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Autoimmune Disorders, Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hidradenitis Suppurativa, Huntington Disease, Inflammatory Bowel Disease, Inflammatory Pain, Lung Cancer, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Neuroinflammation, Neuropathic Pain (Neuralgia), Pain, Periodontitis and Rheumatoid Arthritis.
The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2018, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Complement component 5a receptor 1 (C5AR1) or CD88 is a G protein-coupled receptor for C5a. It functions as a complement receptor. Receptor activation stimulates chemotaxis, granule enzyme release, intracellular calcium release and superoxide anion production.
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 1, 1, 4 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Oncology, Dermatology, Genito Urinary System And Sex Hormones, Infectious Disease, Mouth and Dental Disorders, Musculoskeletal Disorders and Respiratory which include indications Alzheimer's Disease, Allergic Asthma, Amyotrophic Lateral Sclerosis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis), Arthritis, Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), Autoimmune Disorders, Churg-Strauss Syndrome, Glomerulonephritis, Granulomatosis with Polyangiitis (Wegener's Granulomatosis), Hidradenitis Suppurativa, Huntington Disease, Inflammatory Bowel Disease, Inflammatory Pain, Lung Cancer, Membranoproliferative Glomerulonephritis Type II (Dense Deposit Disease), Methicillin-Resistant Staphylococcus aureus (MRSA) Infections, Microscopic Polyangiitis (MPA), Neuroinflammation, Neuropathic Pain (Neuralgia), Pain, Periodontitis and Rheumatoid Arthritis.
The latest report C5a Anaphylatoxin Chemotactic Receptor 1 - Pipeline Review, H2 2018, outlays comprehensive information on the C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- The report reviews C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics and enlists all their major and minor projects
- The report assesses C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
AFFiRiS AG
ChemoCentryx Inc
Dompe Farmaceutici SpA
Innate Pharma SA
Integral Molecular Inc
MorphoSys AG
Prommune Inc
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
ALS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2593A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize C5AR1 for Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize C5AR1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target C5a for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News & Press Releases
May 23, 2018: ChemoCentryx Announces Presentation On Avacopan at the 55th ERA-EDTA Congress
Apr 11, 2018: ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
Jan 04, 2018: Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
Nov 03, 2017: ChemoCentryx Presents Data On Avacopan at ASN Kidney Week 2017
Sep 11, 2017: Innate Pharma Presents New Preclinical Data For IPH5401 at 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy conference
Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan
May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan
Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR’ and ‘CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan’)
Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy
Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016
Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance
Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development
Jun 01, 2016: ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
AFFiRiS AG
ChemoCentryx Inc
Dompe Farmaceutici SpA
Innate Pharma SA
Integral Molecular Inc
MorphoSys AG
Prommune Inc
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
ALS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2593A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IPH-5401 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize C5AR1 for Immunological Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize C5AR1 for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestinal, Autoimmune and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Vaccine to Target C5a for Alzheimer's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Anaphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News & Press Releases
May 23, 2018: ChemoCentryx Announces Presentation On Avacopan at the 55th ERA-EDTA Congress
Apr 11, 2018: ChemoCentryx Announces Presentation During National Kidney Foundation 2018 Spring Clinical Meeting
Jan 04, 2018: Avacopan Conditional Marketing Authorization Application Accepted for Regulatory Review by European Medicines Agency
Nov 03, 2017: ChemoCentryx Presents Data On Avacopan at ASN Kidney Week 2017
Sep 11, 2017: Innate Pharma Presents New Preclinical Data For IPH5401 at 3rd CRI-CIMT-EATI-AACR International Cancer Immunotherapy conference
Jun 06, 2017: Oral Presentation at ERA-EDTA Congress Highlighst Fourth Potential Indication for Avacopan
May 23, 2017: ChemoCentryx Granted EU Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Mar 22, 2017: ChemoCentryx Receives FDA Orphan Drug Designation for Avacopan in the Treatment of Debilitating Kidney Disease C3 Glomerulopathy
Jan 09, 2017: ChemoCentryx Provides Update on Lead Program Avacopan
Nov 07, 2016: ChemoCentryx Announces Presentations of Positive Results from Phase II ANCA-Associated Vasculitis Trials (‘CLEAR’ and ‘CLASSIC’) of Orally Administered Complement 5a Receptor Inhibitor CCX168 (‘Avacopan’)
Oct 27, 2016: ChemoCentryx Reports Improvement in Renal Physiology and Stabilization of Kidney Function Following Treatment with Orally Administered Complement Inhibitor CCX168 (Avacopan) in Patient with Refractory C3 Glomerulopathy
Oct 17, 2016: ChemoCentryx Announces Presentation of Positive Data from Ongoing Pilot Phase II Trial of CCX168 (Avacopan) in Atypical Hemolytic Uremic Syndrome at ASN Kidney Week 2016
Jul 13, 2016: UNMC Researcher Secures $2.25 Million Grant to Fight Antibiotic Resistance
Jun 16, 2016: ChemoCentryx Announces Positive Top-Line Results for CCX168 from the Phase II ANCA-Associated Vasculitis CLASSIC Study and Advances Plans to Initiate Phase III Development
Jun 01, 2016: ChemoCentryx Receives European Medicines Agency PRIority MEdicines (PRIME) Designation for Accelerated Assessment of Complement 5a Receptor Inhibitor CCX168 for Treatment of Patients with ANCA-Associated Vasculitis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AFFiRiS AG, H2 2018
Pipeline by ChemoCentryx Inc, H2 2018
Pipeline by Dompe Farmaceutici SpA, H2 2018
Pipeline by Innate Pharma SA, H2 2018
Pipeline by Integral Molecular Inc, H2 2018
Pipeline by MorphoSys AG, H2 2018
Pipeline by Prommune Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indications, H2 2018
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd.1), H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by AFFiRiS AG, H2 2018
Pipeline by ChemoCentryx Inc, H2 2018
Pipeline by Dompe Farmaceutici SpA, H2 2018
Pipeline by Innate Pharma SA, H2 2018
Pipeline by Integral Molecular Inc, H2 2018
Pipeline by MorphoSys AG, H2 2018
Pipeline by Prommune Inc, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Discontinued Products, H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AFFiRiS AG
ChemoCentryx Inc
Dompe Farmaceutici SpA
Innate Pharma SA
Integral Molecular Inc
MorphoSys AG
Prommune Inc
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
AFFiRiS AG
ChemoCentryx Inc
Dompe Farmaceutici SpA
Innate Pharma SA
Integral Molecular Inc
MorphoSys AG
Prommune Inc
